Get the Stockscreener App
0.13
6.39%
0.0064
Cns Pharmaceuticals Inc stock is traded at $0.13, with a volume of 28.71M.
It is up +6.39% in the last 24 hours and down -9.93% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$0.1236
Open:
$0.132
24h Volume:
28.71M
Relative Volume:
2.05
Market Cap:
$5.36M
Revenue:
-
Net Income/Loss:
$-18.61M
P/E Ratio:
-0.0129
EPS:
-10.05
Net Cash Flow:
$-13.91M
1W Performance:
+10.60%
1M Performance:
-9.93%
6M Performance:
-98.78%
1Y Performance:
-99.87%
1-Day Range:
$0.128
$0.145
1-Week Range:
$0.1025
$0.145
52-Week Range:
$0.0955
$135.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CNSP | 0.1289 | 5.36M | 0 | -18.61M | -13.91M | -10.05 |
| VRTX | 447.47 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.21 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.97 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.87 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting - Barchart
CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin - Barchart
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - AccessWire
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results - AccessWire
CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan
CNS Pharmaceuticals Inc (CNSP) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in CNS Pharmaceuticals Inc - GuruFocus.com
CNS Pharmaceuticals: Financial Results and Strategic Moves - TipRanks
CNS Pharmaceuticals’ $3 Million Common Stock Offering - Global Legal Chronicle
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - AccessWire
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Berubicin’s Potential During KOL Connect Event - Barchart
CNS Pharmaceuticals Receives Temporary Exception from NASDAQ Regarding Minimum Bid Price Requirement - Defense World
CNS Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com South Africa
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Yahoo Finance
CNS Pharmaceuticals granted Nasdaq compliance extension - Investing.com
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - Financial Content
CNS Pharmaceuticals faces NASDAQ delisting over price rule By Investing.com - Investing.com Australia
CNS Pharmaceuticals secures $3 million in registered direct offering - Investing.com
CNS Pharmaceuticals secures $3 million in registered direct offering By Investing.com - Investing.com UK
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - AccessWire
CNS Pharmaceuticals faces NASDAQ delisting over price rule - Investing.com
Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.12, Up by 0.77 - The Dwinnex
Can you still get a good price for Cns Pharmaceuticals Inc (CNSP) Shares at this point? - US Post News
CNS Pharmaceuticals (NASDAQ: CNSP) Management Participates In Virtual Investor KOL Connect Segment - Barchart
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum - MSN
It is Poised to be a Bull Market for Cns Pharmaceuticals Inc (CNSP) - SETE News
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - BioSpace
Ladenburg Thalmann gives a Neutral recommendation for Cns Pharmaceuticals Inc (CNSP) - Knox Daily
Cns Pharmaceuticals Inc (CNSP) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC - StockTitan
A stock that deserves closer examination: Cns Pharmaceuticals Inc (CNSP) - US Post News
Ratio Examination: Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - The Manila Times
Wall Street analysts’ outlook for Cns Pharmaceuticals Inc (CNSP) - SETE News
Cns Pharmaceuticals Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Titan Medical Inc (TMD-T) QuotePress Release - The Globe and Mail
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 - The Manila Times
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - ForexTV.com
Cns Pharmaceuticals Inc (CNSP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Examining Cns Pharmaceuticals Inc (CNSP) stock is warranted - US Post News
CNS Therapeutics Market 2024 Share, Growth Forecast and Industry Outlook 2032 | Eli Lilly and Co. - 대구포스트
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
A new trading data show Cns Pharmaceuticals Inc (CNSP) is showing positive returns. - SETE News
Do investors need to be concerned about Cns Pharmaceuticals Inc (CNSP)? - US Post News
CNS (Central Nervous System) Therapeutics Market 2024 Size, Status and Global Outlook 2031 - Newstrail
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum - AccessWire
Ratio Review: Analyzing Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cns Pharmaceuticals Inc Stock (CNSP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Evans Carl Anthony | Director |
Feb 01 '24 |
Buy |
0.30 |
33,333 |
10,000 |
33,458 |
| Downs Christopher | Chief Financial Officer |
Feb 01 '24 |
Buy |
0.30 |
66,666 |
20,000 |
103,438 |
| Climaco John M | Chief Executive Officer |
Feb 01 '24 |
Buy |
0.30 |
166,666 |
50,000 |
215,676 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):